{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:47:20Z","timestamp":1777355240790,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.7759\/cureus.28690","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T13:09:07Z","timestamp":1662124147000},"source":"Crossref","is-referenced-by-count":1,"title":["Myelodysplastic Syndrome in a Patient With Common Variable Immunodeficiency: A Rare Occurrence"],"prefix":"10.7759","author":[{"given":"Nihas R","family":"Mateti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju K","family":"Vaddepally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav B","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya Elsa","family":"Skaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-009-0051-0","article-title":"Autoimmunity in common variable immunodeficiency","volume":"9","author":"Agarwal S","year":"2009","unstructured":"Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009, 9:347-52. 10.1007\/s11882-009-0051-0","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272351","article-title":"Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?","volume":"116","author":"Vajdic CM","year":"2010","unstructured":"Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?. Blood. 2010, 116:1228-34. 10.1182\/blood-2010-03-272351","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.024","article-title":"Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry","volume":"141","author":"Mayor PC","year":"2018","unstructured":"Mayor PC, Eng KH, Singel KL, et al.. Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018, 141:1028-35. 10.1016\/j.jaci.2017.05.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1243","article-title":"Myelodysplastic syndrome (MDS) and acute lymphocytic leukemia in common variable immunodeficiency (CVID)","volume":"135","author":"Toh J","year":"2015","unstructured":"Toh J, Rubinstein A, Verma AK, Bakirhan K. Myelodysplastic syndrome (MDS) and acute lymphocytic leukemia in common variable immunodeficiency (CVID). J Allergy Clin Immunol. 2015, 135:95. 10.1016\/j.jaci.2014.12.1243","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8416124","article-title":"Global distribution of common variable immunodeficiency (CVID) in the light of the UNDP Human Development Index (HDI): a preliminary perspective of a rare disease","volume":"2020","author":"Weifenbach N","year":"2020","unstructured":"Weifenbach N, Schneckenburger AA, L\u00f6tters S. Global distribution of common variable immunodeficiency (CVID) in the light of the UNDP Human Development Index (HDI): a preliminary perspective of a rare disease. J Immunol Res. 2020, 2020:8416124. 10.1155\/2020\/8416124","journal-title":"J Immunol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I treat common variable immune deficiency","volume":"116","author":"Cunningham-Rundles C","year":"2010","unstructured":"Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010, 116:7-15. 10.1182\/blood-2010-01-254417","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0198-5","article-title":"The 2015 IUIS phenotypic classification for primary immunodeficiencies","volume":"35","author":"Bousfiha A","year":"2015","unstructured":"Bousfiha A, Jeddane L, Al-Herz W, et al.. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015, 35:727-38. 10.1007\/s10875-015-0198-5","journal-title":"J Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1658523","article-title":"Malignancy in common variable immunodeficiency: a systematic review and meta-analysis","volume":"15","author":"Kiaee F","year":"2019","unstructured":"Kiaee F, Azizi G, Rafiemanesh H, et al.. Malignancy in common variable immunodeficiency: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2019, 15:1105-13. 10.1080\/1744666X.2019.1658523","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel H","year":"2008","unstructured":"Chapel H, Lucas M, Lee M, et al.. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008, 112:277-86. 10.1182\/blood-2007-11-124545","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg SL","year":"2010","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010, 28:2847-52. 10.1200\/JCO.2009.25.2395","journal-title":"J Clin Oncol"},{"key":"ref11","article-title":"Myelodysplastic Syndrome","author":"Dotson JL","year":"2022","unstructured":"Dotson JL, Lebowicz Y. Myelodysplastic Syndrome. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2017-0002","article-title":"The 2016 revision to the World Health Organization classification of myelodysplastic syndromes","volume":"5","author":"Hong M","year":"2017","unstructured":"Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Int Med. 2017, 5:139-43. 10.1515\/jtim-2017-0002","journal-title":"J Transl Int Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2013.0783","article-title":"Myelodysplastic syndromes: diagnosis, prognosis, and treatment","volume":"110","author":"Germing U","year":"2013","unstructured":"Germing U, Kobbe G, Haas R, Gattermann N. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int. 2013, 110:783-90. 10.3238\/arztebl.2013.0783","journal-title":"Dtsch Arztebl Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2021-0002","article-title":"Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia","volume":"10","author":"Liu M","year":"2021","unstructured":"Liu M, Wang F, Zhang Y, et al.. Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia. Int J Hematol Oncol. 2021, 10:IJH34. 10.2217\/ijh-2021-0002","journal-title":"Int J Hematol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg PL","year":"2017","unstructured":"Greenberg PL, Stone RM, Al-Kali A, et al.. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017, 15:60-87. 10.6004\/jnccn.2017.0007","journal-title":"J Natl Compr Canc Netw"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711435659","article-title":"Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion","volume":"3","author":"Duong VH","year":"2012","unstructured":"Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 2012, 3:105-16. 10.1177\/2040620711435659","journal-title":"Ther Adv Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101623-myelodysplastic-syndrome-in-a-patient-with-common-variable-immunodeficiency-a-rare-occurrence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:04Z","timestamp":1707507604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101623-myelodysplastic-syndrome-in-a-patient-with-common-variable-immunodeficiency-a-rare-occurrence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.28690","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}